Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin + daratumumab, lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
2021-006792-42Phase 2Active
- Sponsor
- Hellenic Society of Hematology
- Start
- Feb 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoints: Safety and tolerability (dose finding, DLT evaluation) and Clinical activity (efficacy). Started Feb 2022; status: active.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-006792-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006792-42.